Skip to content

Conservative Therapy of Proximal Phalanx Fractures - Comparing the Lucerne Cast With Finger Splinting

Conservative Therapy of Proximal Phalanx Fractures - a Prospective Randomized Study Comparing the Lucerne Cast With Finger Splinting

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06022419
Acronym
LuCa
Enrollment
86
Registered
2023-09-01
Start date
2023-10-01
Completion date
2028-02-29
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proximal Phalanx Fracture

Brief summary

The purpose of this prospective randomized controlled clinical trial is to evaluate if the lucerne cast leads to a better functional outcome than a forearm cast with a finger splint in patients with a proximal phalanx fracture.

Detailed description

This study represents a prospective randomized controlled clinical trial comparing two different conservative treatment options in patients with proximal phalanx fractures. Patients meeting the inclusion criteria will be enrolled in the present study provided they give their consent. Informed written consent will be obtained. Randomization will be performed according to the CONSORT Guidelines of Prospective Randomized Trials using the software Randomizer by the Medical University of Graz. Patients allocated to the control group will receive a forearm cast with a finger splint, while patients in the study group will receive the lucerne cast. Both groups will receive the allocated cast for 4 weeks. Clinical outcome will be assessed 12 weeks after trauma.

Interventions

PROCEDURELucerne Cast

Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.

Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Proximal phalanx fracture in the fingers (II - V) * Patient age between 18 and 70 years

Exclusion criteria

* Condylar fracture * Avulsions of the collateral ligament * Pathologic fracture * Intraarticular fracture * Patients unable to consent * Polytraumatized patients * Patients initially presenting more than 7 days after injury * Pregnancy * Compound fractures * Multiple hand injuries

Design outcomes

Primary

MeasureTime frameDescription
Brief Michigan-Hand-Outcome-Questionnaireat 12 weekspatient-based standardised questionnaire (12 items, range 0-100, 100=ideal function, 0=poorest function)

Secondary

MeasureTime frameDescription
Treatment Failureat 1, 2, 4 and 12 weeksOccurrence of indication for surgery (malrotation, axial deviation \>10°, dorsal angulation \>20°) after primary reposition

Other

MeasureTime frameDescription
Strength Measurementat 4 and 12 weeksdynamometer-based strength evaluation
Range of Motion (ROM) Assessmentat 4 and 12 weeksgoniometer-based ROM evaluation of hand and wrist
Delayed Bone Healingat 12 weeksnumber of participants with bone non-union at end of study
Radiological Outcomeat 0, 1, 2, 4 and 12 weeksx-ray based outcome of fracture healing in terms of axial deviation (measured in °)
Quick DASH-Scoreat 0, 1, 2, 4 and 12 weekspatient-based standardised questionnaire (11 items, range 0-100, 100=ideal function, 0=poorest function)
Brief Michigan-Hand-Outcome-Questionnaireat 0, 1, 2 and 4 weekspatient-based standardised questionnaire (12 items, range 0-100, 100=ideal function, 0=poorest function)
Occurrence of Complicationsat 0, 1, 2, 4 and 12 weeksOccurrence of complications due to treatment
Visual Analogue Scale (VAS)at 0, 1, 2, 4 and 12 weeksPain evaluation on a psychometric response scale (range 0-10, 0=no pain, 10=maximum pain)

Countries

Austria

Contacts

Primary ContactPaul L Hoppe, M.D.
paul.hoppe@meduniwien.ac.at0043 1 40400 59160

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026